{
 "PrintNo":"S6422","Session":2025,"Chamber":"SENATE","BillType":"Senate","Published":"2025-03-13T11:39:12.291686Z",
 "Status":"IN_SENATE_COMM","Committee":"Higher Education",
 "Milestones":[{"Type":"IN_SENATE_COMM","Date":"2025-03-13","Committee":"Higher Education"}],
 "Actions":[{"Text":"REFERRED TO HIGHER EDUCATION","Date":"2025-03-13","Chamber":"SENATE"}],
 "Sponsors":[{"ID":438,"Name":"Brad Hoylman-Sigal","Short":"HOYLMAN-SIGAL"}],
 "Title":"Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy",
 "Summary":"Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.",
 "LawSection":"Education Law","LawCode":"Amd §§6807 & 6810, Ed L; add §280-d, Pub Health L",
 "ActClause":"AN ACT to amend the education law and the public health law, in relation to prescription labels for mifepristone, misoprostol, gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria",
 "SameAsPrintNo":"A6927-2025"
}